UPDATE: Canaccord Genuity Downgrades Meridian Biosciences (VIVO) to Hold; Changing Investment Thesis

July 27, 2012 7:30 AM EDT
Get Alerts VIVO Hot Sheet
Price: $16.75 --0%

Rating Summary:
    3 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VIVO Now!
Join SI Premium – FREE
(Updated - July 27, 2012 1:43 PM EDT)

Canaccord Genuity downgraded Meridian Biosciences (NASDAQ: VIVO) from Buy to Hold. PT lowered from $25 to $18.

Analyst, Jeffrey Frelick, said, "We are downgrading following a FQ3 miss, lower F2012 guidance, and our concerns on modest growth through next year...Although the comp was tough in the quarter, we are more concerned about structural challenges. VIVO’s C. difficile immunoassay business continues to face competitive pressures (mainly Alere (NYSE: ALR)), its sales force struggles defending share, and Illumigene utilization should be more robust with ~900 customers."

2012 Revs/EPS go to $173M/$0.81 from $184M/$0.86; 2013 Revs/EPS go to $185M/$0.85 from $210M/$1.00

For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.

Shares of Meridian Biosciences closed at $16.81 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades

Related Entities

Canaccord Genuity

Add Your Comment